A 15-year-old girl incurs a cut to the sole of her foot after stepping on a piece of broken glass. On examination, a superficial 0.5-cm laceration ceases to bleed within 5 minutes after application of local pressure. Which of the following substances is released by endothelium and is most likely to counteract platelet aggregation near this site of injury?

**Core Concept**
Prostacyclin is a potent vasodilator and inhibitor of platelet aggregation, produced by the endothelium in response to vascular injury. It plays a crucial role in preventing excessive thrombosis and maintaining vascular homeostasis.

**Why the Correct Answer is Right**
Prostacyclin, also known as prostaglandin I2 (PGI2), is synthesized by the enzyme cyclooxygenase-1 (COX-1) in the endothelial cells lining blood vessels. It acts on platelets to inhibit the aggregation of platelets by stimulating the production of cyclic adenosine monophosphate (cAMP), which in turn activates protein kinase A (PKA) and inhibits platelet activation. This process helps to prevent the formation of a blood clot at the site of injury. The release of prostacyclin is triggered by the injury to the endothelium, leading to the relaxation of the smooth muscle cells and vasodilation.

**Why Each Wrong Option is Incorrect**
* **Option A:** Glycoprotein IIb/IIIa is a receptor on the surface of platelets that plays a crucial role in platelet aggregation by binding to fibrinogen and von Willebrand factor, leading to platelet clustering. It is not released by the endothelium and does not counteract platelet aggregation.
* **Option B:** Platelet-activating factor (PAF) is a phospholipid that promotes platelet aggregation and activation, rather than inhibiting it. It is produced by various cells, including platelets, and is involved in inflammatory responses.
* **Option D:** Tissue-type plasminogen activator (t-PA) is an enzyme that catalyzes the conversion of plasminogen to plasmin, leading to the breakdown of blood clots. While t-PA is involved in fibrinolysis, it is not released by the endothelium in response to injury and does not directly counteract platelet aggregation.

**Clinical Pearl / High-Yield Fact**
Prostacyclin has a short half-life and is rapidly metabolized by the enzyme 15-hydroxyprostaglandin dehydrogenase. Its production is often reduced in conditions such as atherosclerosis and diabetes mellitus, leading to impaired vasodilation and increased platelet aggregation.

✓ Correct Answer: C. Prostacyclin

✓ Correct Answer: C. Prostacyclin